Abstract Because previous studies show that lipoproteins affect platelet aggregation, we studied the effect of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) on the binding of fibrinogen, which mediates platelet-platelet contact. Neither LDL nor HDL induced "I-fibrinogen binding at concentrations up to 2 g protein/L. In contrast, platelets stimulated with 10 jimol/L ADP bound 63 734±2453 molecules of fibrinogen per platelet. A 5-minute preincubation with LDL (0.5 to 2 g/L protein) induced a dose-dependent increase to 91 3O7±2164 molecules of fibrinogen per platelet at 1.5 g/L, which is in the range found after optimal stimulation with a-thrombin. The increased fibrinogen binding in the presence of LDL resulted in faster aggregation with a 16% increase in single platelet disappearance and a faster optical aggregation at 5 /tmol/L ADP and 1.5 g protein/L LDL. Inhibition of prostaglandin Gj/Hj-thromboxane A 2 formation with indomethacin (30 jimol/L) did not change the stimulation by LDL. In contrast, modification of h/sine residues of LDL, which is known to prevent specific binding to platelets, completely abolished the effect of LDL. Platelets of patients with an increased level of lowdensity lipoproteins (LDLs), such as in type II hyperlipoproteinemia and familial hypercholesterolemia, 3 are more sensitive to aggregating agents than platelets from normal subjects.
there is a change in conformation 1718 or microenvironment 1719 of the GP complex that makes it accessible to fibrinogen, 20 -22 fibronectin, 22^3 von Willebrand factor, 22 -24 and vitronectin. 25 - 26 Fibrinogen forms bridges between platelets leading to the formation of aggregates.
In the present study we investigated the effect of isolated lipoproteins on the ADP-induced exposure of fibrinogen binding sites on the GPIIB/IIIA complex. Our data showed that LDL but not HDL enhanced the exposure of fibrinogen binding sites via a mechanism that is different from the effect of LDL on platelet secretion.
Methods

Materials
Indomethacin, phenylmethylsulfonyl fluoride, imipramine, and a-thrombin were purchased from Sigma, St Louis, Mo, and ADP and the "Monotest cholesterol" were from Boehringer Mannheim, Mannheim, FRG. Fibrinogen (grade L) was from Kabi, Stockholm, Sweden, and Na l23 I (specific activity, 629 GBq/mg) and [ through a Sepharose 2B column equilibrated in calcium-free Tyrode's solution (137 mmol/L NaCl, 2.68 mmol/L KC1, 0.42 mmol/L NaH 2 PO 4 , 1.7 mmol/L MgCl 2> and 11.9 mmol/L NaHCO 3 , pH 7.25) containing 0.2% bovine serum albumin (demineralized) and 0.1% glucose.
Preparation of '"I-Labeled Fibrinogen
Fibrinogen was made fibrin-and fibronectin-free by passage through a gelatin-Sepharose 4B column. The isolated fibrinogen was radiolabeled with Na 125 I by a modified Iodo-Gen method. Details of these procedures have been described. 27 
Isolation of LDL and HDL
LDL {d, 1.019 to 1.063 g/mL) and HDL (d, 1.063 to 1.225 g/mL) were isolated from fresh citrate-phosphate-dextrose plasma from six random donors by sequential flotation in a Beckman L-80 ultracentrifuge. To prevent oxidation and bacterial contamination, 0.25 mmol/L phenylmethylsulfonyl fluoride, 0.2 mmol/L thimerosal, 2 mmol/L NaN 3 , and 0.4 mmol/L EDTA (all final concentrations) were added to the plasma. Subsequent centrifugations (20 hours at 175 OOOg at 18°Q were carried out in the presence of sodium azide and EDTA. Potassium bromide was used for density adjustment. Lipoproteins were dialyzed against buffer containing 150 mmol/L NaCl, 1 mmol/L EDTA, and 0.3 mmol/L NaN 3 and were subsequently filtered through a 0.45-^m filter. Isolated LDL and HDL were stored for not more than 14 days at 4°C, and before the incubation studies with platelets the lipoproteins were dialyzed a second time overnight against 150 mmol/L NaCl. The final preparation was devoid of appreciable amounts of oxidized LDL; compared with a sample concurrently dialyzed in the presence of 10 junol/L EDTA, diene formation induced by 20 junol/L CuSO 4 was within the experimental error of the control. 28 Contamination with endotoxins was below detection limits (less than 3 pg/mL). 29 The protein content of the lipoproteins was determined by using the procedure of Lowry et al. 30 
Lysine Modification of LDL
Lysine residues in the cell-binding domain of LDL were modified by carbamoylation with cyanate. This treatment abolishes the specific binding of LDL to platelets. 31 Details of this procedure are described by Weisgraber et al. 32 Lipoproteins (2 to 5 g protein/mL) in 150 mmol/L NaCl and 0.27 mmol/L EDTA were diluted with 0.5 vol 0.3 mol/L sodium borate buffer, pH 8.0. Potassium cyanate (20 g/1 g protein) was added to the lipoprotein solution, and the mixture was incubated at 35°C for 2 hours. Excess reagent was removed by dialysis at 4°C against 150 mmol/L NaCl and 0.27 mmol/L EDTA, pH 7.0, for 36 hours.
Platelet Stimulation and Binding of '"I-Fibrinogen
Gel-filtered platelets (GFPs; 200 to 300x10 3 pIatelets//iL) were stimulated at 22°C with 10 ;tmol/L ADP or 0.1 U/mL a-thrombin in the presence of 1 junol/L 1B I-fibrinogen and without stirring. To prevent coagulation, 30 nmol/L PPACK (final concentration) was added 3 minutes after the addition of o-thrombin.
To investigate the effect of LDL, HDL, and h/sine-modified LDL, GFPs were preincubated with different concentrations of these lipoproteins (2 g protein/L) for 5 minutes at 22°C without stirring. Subsequently, these platelets were stimulated with 10 /xmol/L ADP and incubated with 1 /unol/L radiolabeled fibrinogen for 5 to 60 minutes at 22°C without stirring.
The binding of fibrinogen was measured by placing 200 -/tL samples of cell suspension (in triplicate) on top of 100 /iL 25% (wt/vol) sucrose in calcium-free Tyrode's solution in microsedimentation tubes (Sarstedt, Vienna, Austria) and separating the cells from the medium by centrifugation (12 OOOg for 2 minutes at 22°C) in a Beckman MicTofuge E. The tip of the tube (pellet fraction) was cut off and the pellet and supernatant were counted in a gamma counter. The number of molecules bound per platelet was calculated from the radioactivity in the pellet fraction compared with the total activity in the pellet plus supernatant. The data were corrected for nonspecific binding, which was defined as the binding of l23 I-fibrinogen to unstimulated platelets. The nonspecific binding measured with a 100-fold excess of nonlabeled fibrinogen is identical to the binding of fibrinogen to unstimulated platelets. 27 Details have been described elsewhere.
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Single Platelet Disappearance and Optical Aggregation
GFPs (approximately 200 x 10 3 platelets/jtL) were incubated with different concentrations of LDL (0 to 2 g protein/L) for 5 minutes at 22°C. The platelets were preheated at 37°C for 1 minute and subsequently stimulated with ADP (1 to 10 /tmol/L) in the presence of 1 /rniol/L fibrinogen at 37°C in a Chrono-Log lumiaggregometer (Chrono-Log Corporation, Havcrtown, Pa) at a stirring speed of 900 rpm. Aggregation was measured as single platelet disappearance. 35 Samples were collected 15 seconds after addition of the agonist and were immediately fixed with 9 vol ice-cold 0.5% glutaraldehyde in 0.9% N a d . The platelets were counted in a platelet analyzer (model 810, Baker Instruments, Allentown, Pa) with apertures set at 3.2 and 16 jun\ Optical aggregation was monitored in a Chrono-Log lumiaggTegometer at 37°C at a stirring speed of 900 rpm. Changes of light transmission in the platelet suspension were recorded.
Measurement of Dense Granule Secretion
For the measurement of dense granule secretion, plateletrich plasma was incubated with 1 //jnol/L [ l4 C]serotonin for 30 minutes at 37°C followed by gel filtration on Sepharose 2B (see above). Secretion studies were carried out in the presence of 2.5 jimol/L imipramine to prevent reuptake of serotonin into the platelets. GFPs (150 to 2O0X10 3 platelets/^L) were preincubated with purified LDL (2 g protein/L) for 5 or 30 minutes at 37°C and stimulated with 0.1 to 0.2 U/mL a-thrombin with stirring (900 rpm). At 5 minutes after stimulation samples were collected in 0.15 vol 1.035 mol/L formaldehyde in 150 mmol/L NaCl (0°C, freshly prepared) to stop secretion. After centrifugation (10 OOOg for 1 minute at 4°C), the supematants were collected and used for analysis of [ ]serotonin from unstimulated suspensions after a 30-minute incubation without LDL (less than 3%) and with LDL (6±2%) and were expressed as a percentage of maximal secretable [ l4 C]serotonin, which was measured by incubating samples for 5 minutes at 37°C with 5 U/mL a-thrombin as defined elsewhere.
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Statistics
All data are presented as mean±SD from at least three determinations. Differences were considered significant at a probability value of less than .05 by Student's t test.
Results
Effect of LDL and HDL on the Exposure of Fibrinogen Binding Sites
Stimulation of GFPs with ADP (10 /imol/L) in the presence of 1 ^mol/L 125 I-fibrinogen induced a maximal binding of 63 734±2453 (n=9) fibrinogen molecules per platelet (Fig 1, top) . When isolated platelets were first preincubated for 5 minutes with purified LDL (2 g protein/L, 22°C) and subsequently stimulated with ADP (10 Atmol/L), a binding of 90 363±2461 (n=3) fibrinogen molecules per platelet was found. This number is in the range induced with a-thrombin (98 754 ±4375 same effect was seen after a 30-minute preincubation with 2 g protein/L LDL (10 fj.mo\/L ADP, 69 520±2997; ADP+LDL, 103 277 ±3777 molecules of fibrinogen per platelet; mean±SD, n=3), indicating that a relatively short interaction between LDL and the platelet was sufficient for stimulation of fibrinogen binding.
When LDL was replaced by purified HDL, no effect on ADP-induced fibrinogen binding was observed (Fig  1, bottom) . Furthermore, in the absence of ADP neither LDL nor HDL induced fibrinogen binding (Fig 1) .
When isolated platelets were preincubated with various concentrations of LDL (0.5 to 2 g protein/L) for 5 minutes at 22°C and subsequently stimulated with ADP (10 /imol/L), a concentration-dependent increase in fibrinogen binding was seen (Fig 2) . When platelets were stimulated with lower concentrations of ADP (1 jimol/L, 2.5 /tmol/L, and 5 /xmol/L) there was also an enhancement of fibrinogen binding by LDL that was again dependent on the concentration of LDL. After stimulation with 10 fimo\/L ADP a maximum effect was reached with an LDL concentration of 1.5 g protein/L.
To investigate whether the effect of LDL on the exposure of fibrinogen binding sites was mediated via formation of prostaglandin (PG) G 2 /H 2 and thromboxane A 2 (TXA 2 ), platelets were preincubated with indomethacin (30 ^mol/L for 30 minutes at 37°C) before the addition of LDL. This treatment resulted in binding data that were similar to those of untreated platelets 
Effect of Lysine-Modified LDL on the Exposure of Fibrinogen Binding Sites
Modification of lysine residues in LDL is known to inhibit specific binding to platelets. 31 When GFPs were incubated with lysine-modified LDL and subsequently stimulated with ADP (10 ^mol/L), 74 928±2309 (n=3) molecules of fibrinogen were bound per platelet (Fig 3) . This number was in the same range as observed without LDL (71 631 ±2896, n=3), indicating that LDL stimulated the exposure of fibrinogen binding sites via specific binding to the platelet.
Effect of LDL on Platelet Aggregation
To investigate whether an increased fibrinogen binding in the presence of LDL also resulted in an increased platelet aggregation, we measured the disappearance of single platelets in platelet suspensions stimulated with ADP. A 5-minute preincubation with increasing concentrations of LDL (0 to 2 g protein/L) resulted in a faster disappearance of single platelets at all ADP concentrations tested (Table 1) 
Effect of LDL on [ I4 C] Serotonin Secretion
To investigate whether the increase in fibrinogen binding by LDL was accompanied by a similar effect on the secretion response, the effect of a 5-or 30-minute preincubation with 2 g protein/L LDL on the secretion of ["CJserotonin was investigated. Platelets from different donors were stimulated with different concentrations of o-thrombin to find suspensions that released approximately 40% to 60% of their dense granule contents. 37 As shown in Table 2 , the secretion induced by a-thrombin was not affected by a 5-minute preincubation with LDL, which is in contrast with the effect seen on fibrinogen binding. However, a 30-minute preincubation almost doubled the a-thrombin-induced secretion. Noteworthy is the observation that the effect of LDL on secretion was unchanged after lysine modification of LDL, indicating that LDL increased the secretion response without binding to specific binding sites on the platelets.
Discussion
Several studies report that LDL enhances platelet functions induced by ADP, thrombin, and other plate- ]serotonin-loaded platelets were preincubated with or without 2 g protein/L low-density llpoprotein (LDL) for 5 or 30 minutes at 37 °C. Alternatively, platelets were preincubated with lysine-modified LDL for 30 minutes at 37°C. Subsequently, these platelets were stimulated with 0.1 U/mL a-thrombin. [ 14 C]serotonin secretion (expressed as the percentage of maximal secretable) was measured after a 5-minute stimulation (mean±SD, n=3).
*P<.05 different from control by Student's f test.
let-activating agents. After a 10-to 30-minute preincubation with LDL (one-to twofold the normal concentration of about 0.7 g protein/L), LDL enhances the rate and extent of ADP-induced aggregation and stimulates the secretion of serotonin and TXA 2 formation triggered by thrombin. 1013 - 38 The effect of LDL is explained by facilitating the phospholipase Ar-mediated liberation of arachidonic acid resulting in more PGG 2 /H 2 and TXA 2 production. Indeed, inhibitors of cyclooxygenase or antagonists of PGG 2 /H 2 -TXA 2 receptors block the stimulation by LDL, but since the effect was incomplete, a second, indomethacin-insensitive mechanism had to be involved. 37 - 39 The nature of this second mechanism is still obscure.
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Our present data showed that a 5-minute preincubation with purified LDL induced a dose-dependent increase in ADP-induced fibrinogen binding. At 1.5 g LDL protein/L the increase was maximal and reached the extent seen after optimal stimulation with thrombin. Landolfi et al 40 and Peerschke et al 41 show that the rate and extent of ADP-induced aggregation are determined by the number of bound fibrinogen molecules. Similar results were obtained by measuring surface-bound fibrinogen with an anti-fibrinogen antibody. 42 Thus, the increased binding seen in the presence of LDL in our present experiments explains the increased ADP aggregation observed in earlier studies. 911 The stimulation of fibrinogen binding by LDL also provides an explanation for the increased aggregation tendency seen in patients with increased levels of LDL, such as type II hyperlipoproteinemia and familial hypercholesterolemia. 5 Essentially the same enhancement by LDL was observed in platelets treated with indomethacin. Thus, although formation of PGG 2 /H 2 and TXA 2 is thought to mediate at least part of the activating properties of LDL, this pathway does not appear to affect the regulation of GPIIB/IIIA.
So far it has been difficult to clarify how LDL modulates the activation mechanisms of the platelet. Binding studies with 1 g iodonated LDL protein/L show saturation of specific binding sites on platelets within 2 minutes at 22°C. 43 Under our experimental conditions (a preincubation of 5 minutes with an LDL concentration of 0.5 to 2 g protein/L at 22°C), the LDL binding sites are probably fully occupied, which favors the concept that LDL enhances fibrinogen binding via a receptor-mediated event. The fact that LDL lost its activating properties after modification of lysine residues, which appear essential for specific binding, also points to a receptor-mediated mechanism that controls the exposure of binding sites on GPIIB/IIIA. Activation of protein kinase C (PKC) plays a major role in the exposure of GPIIB/IIIA. 45 LDL attenuated the increase in cyclic AMP induced by prostacyclin, we found an equally rapid closure of binding sites by 1 to 10 nmol/L prostacyclin with and without LDL (1 g protein/L), indicating that the modulation of GPIIB/IIIA by LDL appears independent of this control mechanism (data not shown). Thus, the mechanism by which LDL affects exposure of fibrinogen binding sites must be sought in the effect of LDL on PKC.
LDL potentiates the binding of MG-63 cells to immobilized fibronectin. 46 The stimulation by LDL was the same after modification of the cell-binding domain on LDL by acetylation, indicating that this effect differs from stimulation of fibrinogen binding to platelets by LDL. 46 This may be due to the fact that the LDL receptor on platelets differs from the LDL receptor on nucleated cells. 47 Koller et al 48 report that LDL binds directly to the GPIIB/IIIA complex of platelets, providing a means to activate the complex independently of intracellular signal processing. Their evidence is based on binding studies with biotinylated fibrinogen to GPIIIA blotted on nitrocellulose. Both LDL and HDL blocked the binding of fibrinogen to GPIIIA completely, suggesting that they share binding sites on GPIIIA with fibrinogen. In the present study no effect of HDL was found, whereas LDL increased the binding of fibrinogen instead of inducing inhibition. Blotting of GPIIB/IIIA on nitrocellulose probably causes the complex to assume a different conformation than that seen in intact platelets.
Assuming that LDL changed the exposure of GPIIB/ IIIA via intracellular mechanisms, one might expect a similar potentiation of the secretion responses. We investigated this possibility by using a-thrombin as a stimulus, since ADP induced little secretion in GFPs. The incubation temperature was raised to 37°C to improve standardization of the secretion response. A 5-minute preincubation with LDL (2 g protein/L) had no effect on the [ When the lysine residues in the cell-binding domain of LDL were modified, LDL did not lose its potentiating effect on secretion. Hence, the stimulation of [ u C]serotonin secretion by LDL differs in two aspects with the effect on fibrinogen binding. First, it requires a long LDL-platelet contact and second, it does not require interaction with specific binding sites for LDL on platelets. These observations raise the possibility that LDL
